Online inquiry

IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5443MR)

This product GTTS-WQ5443MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets tcdA gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_009902072.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299391
UniProt ID P16154
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5443MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13358MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ7225MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ4821MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ1836MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ14429MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ3095MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ8233MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ14825MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW